By Finance Pulse in NVO —

Novo Nordisk Loses $70 Billion in Market Cap Amid Obesity Drug Setback

Novo Nordisk experiences a $70 billion market cap loss following disappointing trial results for its obesity treatment. Discover the financial impact and future outlook.

A dramatic visual of a falling stock chart with Novo Nordisk's logo subtly integrated in the background, symbolizing financial decline and a challenging year.
Novo Nordisk Loses $70 Billion in Market Cap Amid Obesity Drug Setback

Novo Nordisk faced a tough year with a significant market cap loss and disappointing trial results.

Source